Published in J Alzheimers Dis on January 01, 2017
White matter signal abnormalities in former National Football League players. Alzheimers Dement (Amst) (2017) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage (1999) 40.38
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron (2002) 33.99
Automatically parcellating the human cerebral cortex. Cereb Cortex (2004) 18.32
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Sequence-independent segmentation of magnetic resonance images. Neuroimage (2004) 11.36
Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging (2001) 8.14
The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ (2010) 7.93
Accurate and robust brain image alignment using boundary-based registration. Neuroimage (2009) 6.27
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage (2010) 4.55
Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry (2001) 4.51
Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol (2013) 4.29
Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke (2004) 3.80
Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology (2006) 3.22
Cerebral white matter lesions and the risk of dementia. Arch Neurol (2004) 3.17
The pathobiology of vascular dementia. Neuron (2013) 3.07
White matter lesions impair frontal lobe function regardless of their location. Neurology (2004) 2.77
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol (2002) 2.27
Regional white matter volume differences in nondemented aging and Alzheimer's disease. Neuroimage (2008) 2.23
Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol (1990) 2.18
The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals. Neuroimage (2004) 2.04
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke (1988) 1.85
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain (2013) 1.64
Age-associated reductions in cerebral blood flow are independent from regional atrophy. Neuroimage (2010) 1.55
Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res (2009) 1.48
White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol (2013) 1.47
White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry (1999) 1.45
Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol (2012) 1.44
Structural neuroimaging in Altheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci (2009) 1.38
Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology (2013) 1.29
Coevolution of white matter hyperintensities and cognition in the elderly. Neurology (2012) 1.28
Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord (2004) 1.22
What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc (2015) 1.19
Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging (2014) 1.08
The effect of white matter lesions on cognition in the elderly--small but detectable. Nat Clin Pract Neurol (2007) 1.07
Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology (2015) 1.05
Regional quantification of white matter hyperintensity in normal aging, mild cognitive impairment, and Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 1.04
White matter hyperintensities in dementia of Alzheimer's type and in healthy subjects without cerebrovascular risk factors. A magnetic resonance imaging study. Arch Neurol (1990) 1.00
MR signal abnormalities in memory disorder and dementia. AJNR Am J Neuroradiol (1990) 0.99
Executive dysfunction in Alzheimer disease. Arch Neurol (2004) 0.94
Incidental brain lesions on magnetic resonance imaging and neurobehavioral functions in the apparently healthy elderly. Stroke (1992) 0.91
Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. J Neural Transm Suppl (1998) 0.91
The relationship between cortical blood flow and sub-cortical white-matter health across the adult age span. PLoS One (2013) 0.90
Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and "pure" Alzheimer disease. Am J Geriatr Psychiatry (2013) 0.89
Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol (2014) 0.87
White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. Dement Geriatr Cogn Disord (2011) 0.83
Magnetic resonance imaging of fixed post mortem brains reliably reflects subcortical vascular pathology of frontal, parietal and occipital white matter. Neuropathol Appl Neurobiol (2013) 0.82
Magnetization transfer ratio of white matter hyperintensities in subcortical ischemic vascular dementia. AJNR Am J Neuroradiol (1999) 0.81
Periventricular hyperintensities are associated with elevated cerebral amyloid. Neurology (2016) 0.81
White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters. Neurobiol Aging (2015) 0.81
Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. Neurobiol Aging (2014) 0.79
White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. J Alzheimers Dis (2015) 0.79
Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly. Front Aging Neurosci (2015) 0.76
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA (2017) 2.58
Common genetic variants influence human subcortical brain structures. Nature (2015) 2.40
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav (2012) 1.97
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav (2012) 1.88
STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal (2013) 1.85
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 1.82
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol (2016) 1.76
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement (2010) 1.70
Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain (2015) 1.58
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One (2013) 1.47
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Whole-brain analysis reveals increased neuroanatomical asymmetries in dementia for hippocampus and amygdala. Brain (2016) 1.40
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature (2017) 1.39
APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry (2013) 1.37
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain (2015) 1.36
Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol (2012) 1.33
Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys (2010) 1.28
Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement (2012) 1.27
Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord (2011) 1.27
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A (2013) 1.26
Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (2010) 1.24
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Simultaneous multi-scale registration using large deformation diffeomorphic metric mapping. IEEE Trans Med Imaging (2011) 1.23
A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis (2011) 1.20
Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging (2014) 1.17
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement (2012) 1.16
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. Brain Struct Funct (2013) 1.16
Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurol (2016) 1.15
aBEAT: a toolbox for consistent analysis of longitudinal adult brain MRI. PLoS One (2013) 1.13
An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol (2011) 1.13
Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression. Front Neurosci (2012) 1.10
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
Cortical surface reconstruction via unified Reeb analysis of geometric and topological outliers in magnetic resonance images. IEEE Trans Med Imaging (2013) 1.04
Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J Int Neuropsychol Soc (2014) 1.04
Using manifold learning for atlas selection in multi-atlas segmentation. PLoS One (2013) 1.04
A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry (2013) 1.03
Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav (2012) 1.03
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry (2014) 1.02
Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement (2012) 1.01
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun (2014) 1.01
Transcriptome-guided amyloid imaging genetic analysis via a novel structured sparse learning algorithm. Bioinformatics (2014) 1.01
A sparse structure learning algorithm for Gaussian Bayesian Network identification from high-dimensional data. IEEE Trans Pattern Anal Mach Intell (2013) 1.00
Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. Brain Imaging Behav (2012) 0.99
Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med (2015) 0.99
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain (2016) 0.99
The perfect neuroimaging-genetics-computation storm: collision of petabytes of data, millions of hardware devices and thousands of software tools. Brain Imaging Behav (2014) 0.97
Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. Mol Psychiatry (2013) 0.97
Cascading network failure across the Alzheimer's disease spectrum. Brain (2015) 0.97
The role of visualization and 3-D printing in biological data mining. BioData Min (2015) 0.96
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis (2013) 0.96
A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain (2014) 0.96
Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One (2013) 0.96
Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr (2015) 0.96
Confirmatory factor analysis of the ADNI Neuropsychological Battery. Brain Imaging Behav (2012) 0.95
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94
Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol (2014) 0.93
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One (2013) 0.93
A novel relational regularization feature selection method for joint regression and classification in AD diagnosis. Med Image Anal (2015) 0.92
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain (2015) 0.92
Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul Disord (2013) 0.92
Clinical prediction from structural brain MRI scans: a large-scale empirical study. Neuroinformatics (2015) 0.92
Models of the aging brain structure and individual decline. Front Neuroinform (2012) 0.91
Sparse temporally dynamic resting-state functional connectivity networks for early MCI identification. Brain Imaging Behav (2016) 0.91
Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. Dement Geriatr Cogn Disord (2012) 0.91
Effect of cognitive reserve markers on Alzheimer pathologic progression. Alzheimer Dis Assoc Disord (2013) 0.91
Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes (2015) 0.90
CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav (2012) 0.90
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
Toward a dynamic biomarker model in Alzheimer's disease. J Alzheimers Dis (2012) 0.90
Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav (2013) 0.89
Improved inference in Bayesian segmentation using Monte Carlo sampling: application to hippocampal subfield volumetry. Med Image Anal (2013) 0.89
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. J Alzheimers Dis (2015) 0.89
Nonlinear dimensionality reduction combining MR imaging with non-imaging information. Med Image Anal (2011) 0.88
Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One (2013) 0.88
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med (2013) 0.87
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol (2016) 0.87
Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration. Mol Neurodegener (2013) 0.87
Evaluating Alzheimer's disease progression using rate of regional hippocampal atrophy. PLoS One (2013) 0.87
Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. Brain Imaging Behav (2014) 0.87
Genetic architecture of resilience of executive functioning. Brain Imaging Behav (2012) 0.87
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol (2015) 0.87
Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol (2014) 0.87
The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol (2015) 0.87
Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. J Alzheimers Dis (2012) 0.87
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86
ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Mol Psychiatry (2013) 0.86
Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res (2014) 0.86
Changes in thalamic connectivity in the early and late stages of amnestic mild cognitive impairment: a resting-state functional magnetic resonance study from ADNI. PLoS One (2015) 0.86
Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. Neuroreport (2013) 0.86
Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging (2015) 0.85
NMF-SVM based CAD tool applied to functional brain images for the diagnosis of Alzheimer's disease. IEEE Trans Med Imaging (2011) 0.85